Take the Kidney Risk Quiz at MinuteForYourKidney.Org
Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), today announced that it is an executive sponsor of the National Kidney Foundation’s (NKF’s) newest public awareness campaign which focuses on the 33 percent of American adults at risk for developing dangerous, life-threatening kidney disease. The NKF would like you to dedicate one minute of your day to take the Kidney Risk Quiz. In just 60 seconds, you can find out if you are the 1 in 3 American adults at risk for developing kidney disease and learn what to do next to address your kidney health.
"We are very pleased to support the NKF for leading this initiative to help identify patients at risk for CKD," said Gerrit Klaerner, Ph.D., Tricida’s Chief Executive Officer and President. "Over 37 million people are affected by kidney disease in the United States, and sadly, most are undiagnosed. The serious complications of kidney disease cannot be overstated, and we are proud to contribute to this effort. We urge everyone to spend just 60 seconds to take the Kidney Risk Quiz."
The first step to preventing kidney failure is knowing your risk by taking the quiz. If it shows you may be at risk, two simple tests, one blood and one urine, can let your doctor know how your kidneys are doing. It’s easy to get tested and the results can save your life. The "Are You the 33%" campaign microsite, public service announcement and all creative assets will also be available in Spanish starting September 15th for National Hispanic Heritage Month. Go to MinuteForYourKidneys.org to take the quiz and learn more.
"We are very grateful for the collaboration with Tricida on this major public awareness campaign," said Anthony Gucciardo, Senior Vice President, Strategic Partnerships, National Kidney Foundation. "Our goal with the campaign is to reach the at-risk population so that people can be diagnosed early and stave off the devastating complications of this disease. With dedicated support from corporate sponsors like Tricida, we’re making great strides towards that goal."
CKD is a serious condition characterized by the gradual loss of essential kidney functions over time. In patients with CKD, normal fluid and electrolyte balance can no longer be maintained, and the excretion of metabolic end products, toxins and drugs is impaired. Furthermore, production and secretion of certain enzymes and hormones are disturbed. According to the Centers for Disease Control and Prevention, or CDC, more than 37 million people in the United States are afflicted with CKD, representing an overall prevalence in the adult population of approximately 15%. The incidence of CKD is primarily driven by the increasing prevalence of diabetes and hypertension. The treatment of CKD adds a tremendous financial burden to the United States, with annual Medicare expenses for CKD in 2018 totaling approximately $114 billion, including approximately $79 billion on CKD costs and approximately $35 billion for end-stage renal disease, or ESRD, costs. ESRD is total and permanent kidney failure that is treated with kidney dialysis or with a kidney transplant. There are approximately 750,000 people in the United States living on kidney dialysis or with a kidney transplant and approximately 125,000 new ESRD cases occur annually. Each year kidney disease kills more people than breast cancer or prostate cancer. According to the 2019 United States Renal Data System report, there were approximately 105,000 deaths from ESRD in 2017. There is a significant medical need to slow progression of kidney disease and reduce the number of patients progressing to kidney failure.
Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with CKD. Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. It is estimated to pose a health risk to approximately three million patients with CKD in the United States. Tricida is currently conducting its confirmatory postmarketing trial, VALOR-CKD, of veverimer. The Tricida New Drug Application (NDA) for veverimer has been accepted for review by the U.S. Food and Drug Administration (FDA) through the Accelerated Approval Program. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of August 22, 2020.
For more information about Tricida, please visit www.Tricida.com.
Cautionary Note on Forward-Looking Statements
This press release includes forward-looking statements, including for example, the potential timing for commercial launch of veverimer, the assigned PDUFA goal date of August 22, 2020, and the potential availability of the Accelerated Approval Program. Forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, among others, that we may not be able to achieve upcoming milestones; the cost, timing and results of clinical trials and other studies; that many drug candidates that have completed Phase 3 trials do not become approved drugs on a timely or cost effective basis, or at all; there can be no assurance that the FDA would approve an NDA through the Accelerated Approval Program, or at all, and even if approval for a drug is obtained, there can be no assurance that it will be adopted in the market or accepted as a benefit to patients and healthcare providers; possible safety and efficacy concerns; and that we completely rely on third-party suppliers and manufacturers for many aspects of our business. These and other factors that may affect our future results of operations are identified and described in more detail in our filings with the Securities and Exchange Commission (SEC), including our Quarterly Reports on Form 10-Q and our Annual Report on Form 10-K. The forward-looking statements contained in this press release reflect Tricida’s current views with respect to future events, and Tricida does not undertake and specifically disclaims any obligation to update any forward-looking statements.
Jackie Cossmon, IRC
Senior Vice President of Investor Relations and Communications